isoxazoles has been researched along with Liver Dysfunction in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gu, J; Hackling, M; Nidamarthy, PK; Prince, WT; Reis da Silva Torrao, L; Shah, B; Stringer, R; Woessner, R | 1 |
| Irkorucu, O; Kilavuz, H; Tanriverdi, B; Tolun, FI; Turan, U; Yaman, A; Yaylali, A; Yener, MK; Yoldas, A | 1 |
| Cai, W; Chen, S; Liu, Y; Tian, X; Wang, W; Wang, Y; Xiao, Y | 1 |
| Anderson, AL; Balasubramaniyan, N; D'Alessandro, A; Devereaux, MW; El Kasmi, KC; Ghosh, S; Orlicky, DJ; Shearn, CT; Sokol, RJ; Suchy, FJ | 1 |
| Alphs, L; Amatniek, J; Canuso, CM; Deutsch, SI; Henderson, DC; Mao, L; Mikesell, C; Rodriguez, S; Sheehan, J | 1 |
| Huang, WQ; Ma, Y; Xu, KQ; Zhang, T | 1 |
| Buist-Homan, M; Faber, KN; Groen, AK; Koehorst, M; Moshage, H; Verhaag, EM | 1 |
| Alawad, AS; Levy, C | 1 |
| Boom, S; Cleton, A; Crauwels, H; Eerdekens, M; Janssens, L; Molz, KH; Talluri, K; Thyssen, A | 1 |
| Demircan, M; Fadillioglu, E; Gülsul, C; Karadag, N; Karaman, A; Kirimlioglu, H; Tas, E | 1 |
| Hirohata, S | 1 |
| Jin, Y; Li, CY; Li, J; Xu, SY; Yao, HW; Zhang, YF | 1 |
| Alsalameh, S; Burian, M; Geisslinger, G; Mahr, G; Woodcock, BG | 1 |
| Bitton, A; Ernst, P; Hudson, M; Kezouh, A; Suissa, S | 1 |
| Britto, MR; Mainka, MB; Parivar, K; Sarapa, N | 1 |
| Choi, K; Khosla, C; Kosek, JC; Omary, MB; Siegel, M; Strnad, P; Toivola, DM | 1 |
| Amariles, P; Lacampa, P; Saez-Benito, L | 1 |
| Heykants, J; Mannens, G; Meuldermans, W; Snoeck, E | 1 |
| Ardalan, B; Belt, RJ; Benjamin, RS; McGovren, JP; Ohnuma, T; Pratt, EA; Taylor, SA | 1 |
3 review(s) available for isoxazoles and Liver Dysfunction
| Article | Year |
|---|---|
FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2016 |
[Efficacy of leflunomide].
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Double-Blind Method; Humans; Isoxazoles; Leflunomide; Liver Diseases; Methotrexate; Mice; Sulfasalazine | 2002 |
Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biological Availability; Bone Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Dysmenorrhea; Female; Humans; Isoenzymes; Isoxazoles; Liver Diseases; Male; Membrane Proteins; Middle Aged; Mouth Diseases; Osteoarthritis; Pain; Prostaglandin-Endoperoxide Synthases; Rats; Sulfonamides | 2003 |
3 trial(s) available for isoxazoles and Liver Dysfunction
| Article | Year |
|---|---|
The influence of hepatic impairment on the pharmacokinetics of paliperidone.
Topics: Adult; Aged; Antipsychotic Agents; Blood Proteins; Case-Control Studies; Female; Humans; Isoxazoles; Liver Diseases; Male; Middle Aged; Paliperidone Palmitate; Protein Binding; Pyrimidines | 2009 |
The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.
Topics: Adult; Aged; Area Under Curve; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Half-Life; Humans; Isoxazoles; Lidocaine; Liver Diseases; Male; Matched-Pair Analysis; Metabolic Clearance Rate; Middle Aged; Sulfonamides | 2005 |
Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials.
Topics: Antibiotics, Antineoplastic; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Clinical Trials as Topic; Drug Evaluation; Female; Humans; Isoxazoles; Kinetics; Liver Diseases; Male; Oxazoles | 1985 |
13 other study(ies) available for isoxazoles and Liver Dysfunction
| Article | Year |
|---|---|
Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment.
Topics: Area Under Curve; Benzothiazoles; Humans; Isoxazoles; Liver Diseases | 2022 |
The effect of Farnesoid X receptor agonist tropifexor on liver damage in rats with experimental obstructive jaundice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Benzothiazoles; Isoxazoles; Jaundice, Obstructive; Liver; Liver Diseases; Rats; Rats, Wistar | 2021 |
The Farnesoid X Receptor Agonist Tropifexor Prevents Liver Damage in Parenteral Nutrition-fed Neonatal Piglets.
Topics: Animals; Benzothiazoles; Humans; Isoxazoles; Liver; Liver Diseases; Parenteral Nutrition; Swine | 2021 |
Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition-associated cholestasis in mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; Bile Acids and Salts; Cholestasis; Gene Expression; Gene Expression Regulation; Hepatocytes; Interleukin-1beta; Intestinal Diseases; Isoxazoles; Lipoproteins; Liver Diseases; Macrophage Activation; Macrophages; Male; Mice; Mice, Inbred C57BL; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Parenteral Nutrition; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Signal Transduction | 2022 |
Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.
Topics: Antipsychotic Agents; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Isoxazoles; Liver Diseases; Liver Function Tests; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrimidines; Schizophrenia; Treatment Outcome | 2014 |
Pretreatment of parecoxib attenuates hepatic ischemia/reperfusion injury in rats.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Isoxazoles; Liver; Liver Diseases; Male; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2015 |
Hormesis in Cholestatic Liver Disease; Preconditioning with Low Bile Acid Concentrations Protects against Bile Acid-Induced Toxicity.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cholestasis; Cytokines; Cytoprotection; Hep G2 Cells; Hepatocytes; Hormesis; Humans; Isoxazoles; Liver Diseases; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear; Time Factors; Transcriptional Activation; Tumor Necrosis Factor-alpha; Vitamin K 3 | 2016 |
Effect of leflunomide on liver regeneration after partial hepatectomy in rats.
Topics: Adjuvants, Immunologic; Animals; Catalase; Disease Models, Animal; Hepatectomy; Immunosuppressive Agents; Isoxazoles; Leflunomide; Liver; Liver Diseases; Liver Regeneration; Malondialdehyde; Nitric Oxide; Oxidative Stress; Peroxidase; Protein Carbonylation; Rats; Rats, Wistar; Treatment Outcome | 2010 |
Effect of leflunomide on immunological liver injury in mice.
Topics: Adjuvants, Immunologic; Animals; Isoxazoles; Leflunomide; Lipopolysaccharides; Liver Diseases; Male; Mice; Mice, Inbred Strains; Mycobacterium bovis | 2003 |
Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Chemical and Drug Induced Liver Injury; Female; Follow-Up Studies; Humans; Isoxazoles; Leflunomide; Liver; Liver Diseases; Male; Middle Aged; Retrospective Studies; Risk Factors; Severity of Illness Index; Treatment Outcome; United States | 2004 |
Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation.
Topics: Animals; Cell Size; Chemical and Drug Induced Liver Injury; Dicarbethoxydihydrocollidine; Enzyme Inhibitors; GTP-Binding Proteins; Hepatomegaly; Humans; Inclusion Bodies; Isoxazoles; Keratins; Liver Diseases; Mice; Mice, Inbred C3H; Protein Glutamine gamma Glutamyltransferase 2; Proteins; Transglutaminases | 2006 |
Dosage adjustments in hepatic dysfunction.
Topics: Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Labeling; Humans; Isoxazoles; Liver Diseases | 2007 |
Plasma protein binding of risperidone and its distribution in blood.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Blood Cells; Blood Proteins; Dogs; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Isoxazoles; Kidney Diseases; Liver Diseases; Male; Middle Aged; Orosomucoid; Paliperidone Palmitate; Piperidines; Protein Binding; Pyrimidines; Rats; Rats, Wistar; Risperidone; Serum Albumin | 1994 |